On November 1, the opening ceremony of Porton Biologics’ Gene and Cell Therapy CDMO Platform was held in Suzhou, China.
IMBRUVICA® (ibrutinib) : Pharmacyclics LLC et al v. Zydus Worldwide DMCC
H. Lundbeck v. Sandoz
Lek, a Sandoz company, the generics arm of Novartis, has invested EUR 10 million at its site in Mengeš, Slovenia, to add new laboratories for the development of final dosage forms for biosimilars, quality control, and biopharmaceuticals technical development. With the investment, final dosage forms for biosimilars will now be developed at the site adding to existing capabilities for active pharmaceutical ingredient development (API).